Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
2421 Results for "
decrease
" in MedChemExpress (MCE) Product Catalog:
Products (2421)
2421 Results for "decrease" in MCE Product Catalog:
Cat. No.: HY-187097
Research Areas:
SARS-CoV-2 3CLpro-IN-40 is a SARS-CoV-2 3CL pro inhibitor with an IC50 of 2.041 μM. SARS-CoV-2 3CLpro-IN-40 reduces the expression level of viral nucleocapsid protein and the expression levels of proinflammatory cytokines (IL-6, TNF-α and IFN-β). SARS-CoV-2 3CLpro-IN-40 decreases the RNA level of infectious bronchitis virus. SARS-CoV-2 3CLpro-IN-40 inhibits SARS-CoV-2 infection. SARS-CoV-2 3CLpro-IN-40 reduces the replication level of HCoV-OC43. SARS-CoV-2 3CLpro-IN-40 is applicable to research related to coronavirus infection .
Cat. No.: HY-187719
CAS No.: 318262-42-9
Target:
Research Areas:
NIK-12192 is an orally active inhibitor of vacuolar H +-ATPase. NIK-12192 reduces intracellular pH, decreases lysosomal volume and acidity, and alters the intracellular localization of V-ATPase by inhibiting proton pumps . NIK-12192 induces αvβ5 integrin polarization, cytoskeletal disruption, cell detachment, anoikis-mediated delayed apoptosis and necrosis, a delayed reduction in mitochondrial membrane potential, and lysosomal/phagosomal accumulation. NIK-12192 inhibits tumor cell migration, invasion, and three-dimensional spheroid growth, and enhances the activity of Topotecan (HY-13768). NIK-12192 suppresses spontaneous lung metastasis in vivo. NIK-12192 is used in research related to colon cancer, ovarian cancer, lung cancer, breast cancer, renal cancer, prostate cancer, acute myeloid leukemia, and melanoma .
Cat. No.: HY-189214
Target:
Research Areas:
eNOS activator-1 is an orally active, blood-brain barrier permeable endothelial nitric oxide synthase (eNOS) activator. eNOS activator-1 upregulates eNOS mRNA expression, enhances endogenous NO biosynthesis, and activates the eNOS signaling pathway to maintain blood-brain barrier integrity. eNOS activator-1 upregulates the protein expression levels of PI3K, AKT, p-PI3K, and p-AKT. eNOS activator-1 reduces oxidative stress levels by decreasing lipid peroxidation and restoring antioxidant enzyme activities. eNOS activator-1 upregulates the expression of tight junction proteins ZO-1 and occludin, increases Cav-1 expression, and inhibits MMP-9-mediated blood-brain barrier disruption. eNOS activator-1 can be used in the research of ischemic stroke .
Cat. No.: HY-189470
Research Areas:
Nav1.2-IN-4 is a blood-brain barrier-penetrant NaV1.2 inhibitor (IC50 = 31.21 μM). Nav1.2-IN-4 preferentially blocks the inactivated state of the neuronal voltage-gated sodium channel NaV1.2, inhibiting persistent and resurgent sodium currents associated with epileptogenesis. Nav1.2-IN-4 restores the GABA-glutamate balance by enhancing GABA and reducing glutamate. Nav1.2-IN-4 reduces oxidative stress in brain tissue by increasing GSH and decreasing MDA. Nav1.2-IN-4 protects mice against MES-induced tonic hindlimb extensor seizures and attenuates hippocampal neuronal degeneration in the PTZ kindling model. Nav1.2-IN-4 can be used for research on epilepsy .
Research Areas:
3-Bromocarbazole is an inhibitor of the aryl hydrocarbon receptor (AHR). 3-Bromocarbazole induces the mRNA expression of CYP1A1 and CYP1B1, with EC50 values of 2500 nM and 1100 nM, respectively. 3-Bromocarbazole inhibits motor neuron axon length by downregulating the mRNA transcription levels of α1-tubulin, Gap43, Syn2a and shha in zebrafish larvae. 3-Bromocarbazole reduces central nervous system neurogenesis by downregulating the mRNA transcription levels of elavl3, nrd, mbp and gfap in zebrafish larvae. 3-Bromocarbazole induces developmental neurotoxicity and decreases body length in zebrafish larvae or embryos; at high concentrations, it also reduces hatching rate, and increases mortality and malformation rate. 3-Bromocarbazole can be used in studies related to developmental neurotoxicity and breast cancer .
Research Areas:
Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.
Cat. No.: HY-B0011AR
CAS No.: 148408-66-6
Synonyms: RP-56976 Trihydrate (Standard)
Research Areas:
Docetaxel Trihydrate (Standard) (RP-56976 Trihydrate (Standard)) is the analytical standard of Docetaxel Trihydrate (HY-B0011A). This product is intended for research and analytical applications. Docetaxel Trihydrate (RP-56976 Trihydrate) is an orally active tubulin stabilizer with antitumor activity. Docetaxel Trihydrate is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel Trihydrate binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel Trihydrate induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel Trihydrate induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel Trihydrate can be used in cancer-related research .
Cat. No.: HY-B0011AS
Synonyms: RP-56976-d5 trihydrate
Research Areas:
Docetaxel-d5 trihydrate (RP-56976-d5 trihydrate) is the deuterated-labeled Docetaxel trihydrate (HY-B0011A). Docetaxel Trihydrate (RP-56976 Trihydrate) is an orally active tubulin stabilizer with antitumor activity. Docetaxel Trihydrate is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel Trihydrate binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel Trihydrate induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel Trihydrate induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel Trihydrate can be used in cancer-related research .
Cat. No.: HY-B0426A
CAS No.: 140462-76-6
Synonyms: ALO4943A; KW4679
Target:
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology
Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
Cat. No.: HY-D3144
CAS No.: 2713577-11-6
Target:
Research Areas:
RhBIV is a thermosensitive rhodamine B (RhB)-derived fluorescent probe that fluorescently labels cellular mitochondria and detects mitochondrial temperature in vitro and in vivo. RhBIV contains a quaternized rhodamine B core, which confers a positive charge for binding to the negatively charged mitochondrial membrane, and an ortho-substituted electron-donating piperidine group; at lower temperatures, RhBIV forms an unstable ion pair form under kinetic control and exhibits strong fluorescence, whereas elevated temperature disrupts or partially interrupts the ion pair form, favoring formation of the conjugated RhBV form and leading to loss of fluorescence. RhBIV exhibits decreased fluorescence responsiveness with increasing temperature over the range of 20-42°C. RhBIV enables biological imaging of cells and mice, mitochondrial thermogenesis imaging, dynamic observation in mitochondrial thermogenesis imaging experiments, and non-invasive imaging of mitochondrial function in living animals (Ex/Em = 520/592 nm) .
Cat. No.: HY-D3525
Target:
Research Areas:
BDL-E5 is a fluorescent probe for detecting live induced pluripotent stem cells at the early reprogramming stage. Its detection mechanism involves specific binding to authentic reprogramming cells, which exhibit increased expression of pluripotency and epithelial genes and decreased expression of mesenchymal genes compared to non-reprogramming cells; it appears to co-localize more significantly with the Golgi complex than other organelle markers in reprogramming cells, and it does not require washing after staining to reduce background signals; fluorescence is generated upon binding to these early reprogramming cells, with positive cells appearing 7 days before iPS colonies are visible and stain positive for the conventional pluripotent marker TRA-1-60, and sorting BDL-E5-positive cells enriches populations that generate higher numbers and quality of iPS colonies. Its detection wavelength is Ex/Em = 578/599 nm .
Cat. No.: HY-N18905
CAS No.: 161713-86-6
Category:
Target:
Cat. No.: HY-N6799R
CAS No.: 36519-25-2
Category:
Cat. No.: HY-P0168A
Synonyms: ARA290 acetate
Cibinetide acetate (ARA290 acetate) is a non-hematopoietic Erythropoietin analog. Cibinetide acetate selectively activates the EPOR/CD131 heteromer IRR without activating EPOR homodimers, and exerts neuroprotective effects through β-common receptor signaling. Cibinetide acetate inhibits Cathepsin K/OSCAR/OC-STAMP/DC-STAMP/NFATC1, increases OPG and Alkaline phosphatase, and decreases CD115. Cibinetide acetate modulates SIRT1/NF-κB/IL-1β signaling, reduces inflammatory infiltration and periapical bone loss, protects pancreatic islets, reduces IBMIR-related platelet consumption, and prolongs graft function. Cibinetide acetate extends healthspan and attenuates age-related cardiac and body weight decline. Cibinetide acetate can be used in research on cerebral ischemic stroke, sarcoidosis-associated small fiber neuropathy, and type 1 diabetes .
Cat. No.: HY-P10868A
Synonyms: RLS-0071 TFA
Target:
Research Areas:
Cat. No.: HY-P11892
Research Areas:
c10c-G1V3 is a BRAG2 binder with a Kd value of 7.37 μM. c10c-G1V3 binds to BRAG2, thereby disrupting its interaction with GluA2 and blocking GluA2 endocytosis and AMPAR subunit switching. c10c-G1V3 reduces glutamate-induced intracellular reactive oxygen species (ROS) accumulation and cell apoptosis (apoptosis). c10c-G1V3 decreases infarct volume in the transient middle cerebral artery occlusion model. c10c-G1V3 can be used in studies related to ischemic stroke .
Cat. No.: HY-P12080
CAS No.: 176365-43-8
Target:
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
pUR4 is a recombinant peptide that acts as a fibronectin (FN) inhibitor. pUR4 binds to the N-terminal type I modules of fibronectin, inhibiting the polymerization of soluble fibronectin and its deposition into the extracellular matrix (ECM). pUR4 reduces β1 integrin activation by depleting ECM fibronectin and disrupting FN-β1 integrin coupling. pUR4 attenuates TNF-α-induced endothelial hyperpermeability, maintains endothelial monolayer integrity, and reduces TNF-α-induced cell morphological changes. pUR4 decreases neutrophil adhesion to cardiac endothelial cells, T cell interstitial migration, immune cell infiltration, collagen deposition, and fibroblast activation. pUR4 can be used in research on pathological vascular leakage, heart failure, inflammation, chronic kidney disease, liver fibrosis, and intestinal fibrosis .
Cat. No.: HY-P990552A
Cat. No.: HY-P992410
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
